The Medicines and Healthcare Products Regulatory Agency (MHRA) and the European Medicines Agency have issued a series of warnings related to the use of valproate medicines in pregnancy and the high risk of serious developmental disorders and congenital malformations.^1–5 This message is being reinforced with information and support materials for patients, carers and healthcare professionals.⁶ The materials, which will be available online and as hard copies, are aimed at ensuring that women and girls of childbearing potential taking valproate medicines are aware …